PMID- 27607593
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20231112
IS  - 1746-6318 (Electronic)
IS  - 1746-630X (Print)
IS  - 1746-630X (Linking)
VI  - 12
IP  - 1
DP  - 2017 Jan
TI  - HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and 
      opportunities.
PG  - 89-95
AB  - PURPOSE OF REVIEW: To summarize recent developments for HIV-associated 
      malignancies (HIVAM) in low-income and middle-income countries (LMIC) with 
      particular focus on sub-Saharan Africa (SSA). RECENT FINDINGS: Antiretroviral 
      therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to 
      high-income countries, with aging and growth of HIV-infected populations, 
      declining infectious deaths, increasing cancer deaths, and transitions from 
      AIDS-defining cancers to non-AIDS defining cancers. Despite ART scale-up, the 
      HIVAM burden remains high including an enormous AIDS-defining cancers burden in 
      SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can 
      experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity 
      remains insufficiently understood including virologic, immunologic, and 
      inflammatory features that may be unique to LMIC. For cervical cancer, scale-up 
      of prevention efforts including vaccination and screening is underway, with 
      benefits already apparent despite continuing high disease burden. For non-Hodgkin 
      lymphoma, curative treatment is possible in the ART era even in SSA, and 
      multifaceted approaches can improve outcomes further. For many other prevalent 
      HIVAM, care and research efforts are being established to guide treatment and 
      prevention specifically in LMIC. SUMMARY: Sustained investment for HIVAM in LMIC 
      can help catalyze a cancer care and research agenda that benefits HIV-positive 
      and HIV-negative patients worldwide.
FAU - Chinula, Lameck
AU  - Chinula L
AD  - aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel 
      Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, 
      Blantyre, Malawi.
FAU - Moses, Agnes
AU  - Moses A
FAU - Gopal, Satish
AU  - Gopal S
LA  - eng
GR  - K01 TW009488/TW/FIC NIH HHS/United States
GR  - U54 CA190152/CA/NCI NIH HHS/United States
GR  - R25 TW009340/TW/FIC NIH HHS/United States
GR  - P20 CA210285/CA/NCI NIH HHS/United States
GR  - P30 CA016086/CA/NCI NIH HHS/United States
GR  - U2G PS001965/PS/NCHHSTP CDC HHS/United States
GR  - UM1 CA121947/CA/NCI NIH HHS/United States
GR  - U01 CA121947/CA/NCI NIH HHS/United States
GR  - R21 CA180815/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin HIV AIDS
JT  - Current opinion in HIV and AIDS
JID - 101264945
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - HIV Infections/*complications/drug therapy
MH  - Humans
MH  - Neoplasms/*diagnosis/epidemiology/*therapy
MH  - Treatment Outcome
PMC - PMC5241291
MID - NIHMS841622
COIS- We have no conflicts of interest to declare.
EDAT- 2016/09/09 06:00
MHDA- 2017/08/22 06:00
PMCR- 2018/01/01
CRDT- 2016/09/09 06:00
PHST- 2016/09/09 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
PHST- 2016/09/09 06:00 [entrez]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.1097/COH.0000000000000329 [doi]
PST - ppublish
SO  - Curr Opin HIV AIDS. 2017 Jan;12(1):89-95. doi: 10.1097/COH.0000000000000329.